Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea
Michinori Ogura(Japanese Red Cross Nagoya Daini Hospital), Kensei Tobinai(National Cancer Center), Naokuni Uike(St Mary's Hospital), Kenichi Ishizawa(Yamagata University), Toshiki Uchida(Red Cross Hospital), Fumiko Nagahama, Yusuke Sonehara, Hirokazu Nagai(Tokai University), Won-Seog Kim(Samsung Medical Center), Youko Suehiro(National Hospital Organization Kyushu Cancer Center)
Cited by 15
Related Papers
Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project
|Blood|2011|431
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
|New England Journal of Medicine|2022|342
Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
|Journal of Clinical Oncology|2019|154
Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease
|Annals of Oncology|2014|151
Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study
|Clinical Infectious Diseases|2015|149